Clinical Microbiology and Infection

VOLUME 11, SUPPLEMENT 2, APRIL 2005

15th European Congress of Clinical Microbiology and Infectious Diseases
Copenhagen, Denmark
2–5 April 2005

Page
1 Antibiotic sensitivity testing of anaerobic bacteria – Workshop arranged by ESGARAB
1 History of medical microbiology in Denmark
3 Update on toxoplasmosis (Symposium arranged with ESGT)
3 European guidelines for diagnosis of tick borne diseases (Symposium arranged with ESCAR)
4 Vancomycin- and methicillin-resistant Staphylococcus aureus (VMRSA): how to cope with it in the hospital setting? (Symposium arranged with ESGNI)
4 Management of relapses and outbreaks of Clostridium difficile (Symposium arranged with ESGCD)
5 Antibiotics for lower respiratory tract infections in primary care (Symposium arranged with ESPRIT)
6 Antibiotic use and policies: an in-depth look at ARPAC results (Symposium arranged with ESGAP)
6 Is the commensal anaerobic microflora involved in spreading antibiotic resistance? (Symposium arranged with ESGARAB)
7 Malaria control – what is in the pipeline?
8 Pseudomonas aeruginosa: a rogue bacterium in the intensive care unit (Symposium arranged with ESICM)
8 Tuberculosis: persistence and resistance
9 Clinical microbiology: what’s new in conventional and molecular diagnostics? (Symposium arranged with ESGMD)
9 Antibiotic usage: practices and policy interventions
14 Hepatitis virus
17 From mild to severe respiratory tract infection: what’s new with azalides? (Symposium arranged by PLIVA)
18 Emerging viral infections
20 Advances in febrile neutropenia
23 The impact of beta-lactamases on clinical practice
23 The year in HIV medicine
23 Coping with the severe acute respiratory syndrome
24 Advances in foreign body infections
24 Paediatric infections
26 New typing approaches for MRSA control
28 Pharmacokinetics and pharmacodynamics of antibiotics
30 Genetic typing for important viral infections: recent technological and conceptual developments (Symposium arranged with ESGEM)
31 Modifying the ribosome as a mechanism of resistance (Joint symposium arranged with ICAAC)
32 Patterns of antibiotic stewardship, use and resistance in European hospitals (Joint symposium arranged with ARPAC and ESAC)
33 Combination antifungal therapy (Symposium arranged with EFISG)
33 New diagnostic methods for the laboratory
38 Hospital infection: new sources and solutions
Contents

41 New antibacterials for the decade: strategies to deliver agents with novel actions (Symposium arranged by GlaxoSmithKline)
43 Staphylococcus aureus disease – from basic science to clinical practice
44 Benchmarking nosocomial infections (Symposium co-organised by SHEA and ESGNI)
44 Exotic infections
48 Emergence and molecular evolution of antibiotic resistance
52 Predictors of the clinical course of HIV infection and therapy
55 Antimicrobial growth promoters in food animal production
56 Crosstalk between bacterial pathogens and their host cells
56 Infection control: challenges now and ahead
57 Burkholderia, Pseudomonas and emerging infections in cystic fibrosis
57 Climate and environment: impact on infectious diseases
58 Crimean Congo haemorrhagic fever in south-eastern Europe
59 Computerised decision support for management of bacterial infections
59 Hepatitis C virus: new targets for drug and vaccine development and markers for therapy
60 Focus on Mycobacterium tuberculosis
62 Diagnosis and management of sepsis in the critically-ill patient (Symposium arranged with ISF)
62 MRSA – new challenges in hospital and community settings
66 Focus on extraction and amplification controls in molecular diagnostics
69 New developments in epidemiology of antibiotic resistance
73 Bacterial biofilms
74 Focus on new antibacterials
75 Emerging infections in the immuno-compromised host (Symposium arranged with EORTC/IDSG)
76 Community-acquired MRSA in Europe – evolution at work
77 Recent trends in severe fungal infections
81 Antibiotic and antibiotic resistance mechanisms
85 Infections in the community: epidemiology, diagnosis and outcome
88 Metallo-beta-lactamases: a last frontier for beta-lactams?
89 Social-political consequences of the HIV pandemic: are we turning the tide?
89 Evolution and function of the haemagglutinin of the influenza virus
90 Streptococcus pneumoniae: a clonal war?
90 Recent advances in chlamydiology
92 Resistance to antifungal drugs
93 Emerging enteric pathogens: responding to the challenge
94 Influenza vaccination
96 New drugs to fight the resistance challenge
99 Metallo-beta-lactamases and resistance to carbapenems
106 Epidemiology of ESBL and MBL – I
114 Extended-spectrum beta-lactamase and other beta-lactamases
123 Various antimicrobial agents including disinfectants
127 Urinary tract infections
133 Brucella
136 Toxoplasmosis
136 Antibiotic usage
143 Antibiotic policy intervention
148 Tuberculosis: diagnosis, resistance and immunology
159 Brucella
163 Clinical mycology
171 Clinical use of vaccines
174 Molecular methods for respiratory bacterial pathogens
182 Molecular methods for enteric pathogens
190 HIV
200 HCV: risk factors, diagnosis, clinical presentation and treatment
205 Bacteriology: role of selective media and identification systems
212 16S rRNA
216 Clinical mycology: case reports
221 Enterococci: epidemiology and resistance
230 Epidemiology of ESBL and MBL – II
238 Tigecycline, in vitro studies
246 Sexually transmitted diseases
253 Helicobacter
259 MRSA – virulence, genes, VISA and treatment
264 Training, scientific output in infectious disease
266 Pneumonia
271 Pharmacokinetics/pharmacodynamics of antibacterial drugs
280 Organ transplants
284 Exotic infections – I: case series
291 Infection and immunopathology
292 Staphylococcal infections
299 Mechanisms of resistance in staphylococci
302 Typing and epidemiology of MRSA
314 Antibiotic-resistant pneumococci and streptococci
326 Wound and fungal infections
328 Antibiotic resistance: nosocomial pathogens
334 Difficult to treat nosocomial infections
338 Susceptibility surveillance studies
341 Pharmacokinetics/pharmacodynamics of quinolones
346 Pharmacokinetics/pharmacodynamics of antifungals
350 Infection control: environmental and hand disinfection
354 Exotic infections – II
361 Fungal susceptibility testing
366 Skin and soft tissue infections
376 Fluoroquinolones, in vitro studies
381 Antibacterial susceptibility studies – I
388 Mechanisms of resistance to macrolides
391 Paediatric infections
401 Mechanisms of antibiotic resistance in Gram-negative bacilli
408 Public health, surveillance and geographic information systems
411 Endocarditis
414 Enteric infection
423 Respiratory tract infection
435 Pneumococcal pneumonia
439 Pneumonia in non-HIV immunosuppressed patients
442 Detection of methicillin resistance
449 Infections and diagnosis in non-HIV immunosuppressed patients
456 Mechanisms of resistance to quinolones
461 Antibacterial susceptibility studies – II
469 Antibiotic-resistant community-acquired pathogens – I
478 Fungal diagnostics
483 ELISA-based diagnostics
486 Clostridium difficile
489 Chlamydia trachomatis
494 Hepatitis A, B and E viruses
499 Herpes virus
504 New drugs: in vitro studies
514 New drugs: in vivo studies
516 Pharmacokinetics/pharmacodynamics of anti-staphylococcal drugs
519 Infections in neutropenic patients
524 Procalcitonin, other markers of infection
527 Diagnosis of viral infections: new methods
531 Diagnosis of viral infections: respiratory and herpes viruses
536 Biofilms: pathogenesis and antibiotic susceptibility
546 CNS infections
551 Experimental CNS infections
554 bloodstream infection
561 Catheter-related infections
563 Molecular bacteriology and mycology
569 Antifungal susceptibility studies

### Contents

- Pathogenesis of respiratory tract and other infections
- Adverse drug reactions, probiotics
- Antibiotic-resistant community-acquired pathogens – II
- Pathogenesis of infections
- Non-fermenter Gram-negative bacilli: epidemiology and resistance
- Immunology, host defences, immunotherapy
- Antibiotic resistance: nosocomial pathogens
- Susceptibility testing methods
- Surveillance of nosocomial infections
- Environmental impact on nosocomial infections
- Tuberculosis: clinical aspects and surveillance
- Health care issues, public health, pharmaco-economics
- New drugs
- Pharmacokinetics, pharmacodynamics, drug interactions, tolerability
- In vitro activity of antimicrobial agents
- Mechanisms of action and of resistance of antimicrobial drugs
- Epidemiology of resistance, antibiotic usage
- Community-acquired infections
- Nosocomial infections, infection control
- Infection in the immunocompromised host (except HIV)
- Immunology, host defenses, immunotherapy
- Pathogenesis, animal models including experimental treatment
- Molecular bacteriology (incl. diagnostics)
- Diagnostic methods (other than molecular)
- Mycobacterial infections (incl. diagnostics)
- Fungal infections
- Tropical and parasitic diseases
- Sexually transmitted diseases (except HIV)
- Molecular virology (incl. diagnostics)
- Viral diseases (not HIV, Herpes, Hepatitis)
- AIDS and HIV infection
- Hepatitis
- Herpes virus
- Emerging infectious diseases
- Vaccines
- Infection in transplant recipients
- Paediatric infections
- Author index
- Subject index